Parkinson's Disease Center and Movement Disorders Clinic
Click on the sign to list the poster and platform presentations by year. Then click on the link to view that presentation.
2023
- Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis and retrocollis.
- Spinocerebellar ataxia 21 and phenotypic variability within a single family.
- Apathy and Parkinson's disease motor phenotypes: A preliminary study.
- Precision neurology for dementia.
American Academy of Neurology (AAN)
75th Annual Meeting in Boston, Mass. (April 22-28, 2023)
2022
- Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis subtype of cervical dystonia.
- Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with retrocollis subtype of cervical dystonia.
- Spinocerebellar ataxia 21 and phenotypic variability within a family.
- Neuroanatomical underpinnings of apathy in Parkinson's disease.
- How does head tremor in cervical dystonia change with head position?
- Characteristics and treatment response to onabotulinumtoxinA of patients from CD-PROBE with anterocollis and retrocollis.
- Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis.
[Previously Presented]
- A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
Movement Disorder Society (MDS)
26th International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain (Sept. 15-18, 2022)
International Neurotoxin Association (INA)
Toxins 2022 6th International Conference in New Orleans, La. (July 27-30, 2022)
American Academy of Neurology (AAN)
74th Annual Meeting in Seattle, Wash. (April 2-7, 2022)
2021
- Pilot study to evaluate pimavanserin for the treatment of motor and behavioral symptoms of Tourette syndrome.
- A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
- Tourette syndrome and driving.
- Whole-exome sequencing in a movement disorders clinic.
- The MJFF global genetic Parkinson's disease research resource.
- A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
- Neutralizing antibody conversion with onabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: A meta-analysis.
- A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia.
- Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naive subjects: Results from a phase III study.
Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021)
American Academy of Neurology (AAN)
Virtual 2021 Annual Meeting (April 17-22, 2021)
International Neurotoxin Association (INA)
Virtual Conference (Jan. 16-17, 2021)
<2020
- Cognitive differences between men and women with progressive supranuclear palsy.
- Duration of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: Results from a Phase III study.
- Clinical and neuropsychological correlates of the TETRAS score in DBS patients.
- Addressing challenges of clinical comprehensive genetic testing in Parkinson's disease.
- Treatment patterns in patients with essential tremor.
- Genome-wide association study meta-analysis for Parkinson disease motor subtypes.
[Platform Presentation]
- Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study.
- RECLAIM-DCP: A randomized, double-blind, placebo-controlled study of deutetrabenazine for the treatment of dyskinesia in cerebral palsy in children and adolescents.
- Capturing Parkinson's disease heterogeneity with quantitative mobility measures.
[Platform Presentation]
- Bradykinesia, mitochondrial myopathy and progressive ophthalmoplegia associated with a novel DNM1L mutation.
- Real world experience with novel VMAT2 inhibitors.
- Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.
- Improvement in patient perceived quality of life with daxibotulinumtoxinA for injection in adults with cervical dystonia.
- Predictors of alcohol responsiveness in dystonia.
- Consensus for the measurement of the camptocormia angle.
- Integrated whole exome sequencing and chromosomal microarray in familial Parkinson's disease.
- Accuracy of the International Parkinson Disease and Movement Disorder Society progressive supranuclear palsy diagnostic criteria (IPD-MDS-PSP).
- Genome-wide association study identifies common genetic variants associated with cervical dystonia.
- Erotophonophilia and severe impulse control disorder in a patient with Parkinson's disease.
- Whole exome sequencing in essential tremor.
- Outcomes of week-24 completers and subjects who had follow-up beyond week 24 after a single treatment of daxibotulinumtoxinA for injection (RT002): Results of a phase 2, open-label (level II), dose escalating study in isolated cervical dystonia.
- Cervical dystonia and substance abuse.
- Unilateral versus bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms.
[Platform Presentation]
- Phenomenology of leg stereotypy syndrome.
- Is benign hereditary chorea really benign? Brain-lung-thyroid syndrome caused by NKX2-1 mutations.
- Levodopa induced dyskinesias in neurodegeneration with brain iron accumulation due to a heterozygous mutation in C19orf12.
- Whole exome sequencing in essential tremor.
- A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia.
[Previously Presented]
- Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD probe study.
- Treatable rare movement disorders.
- A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome.
- Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.
- Leg stereotypy disorder: Phenomenology and prevalence.
- Emotion regulation and neuropsychological status in psychogenic subtypes.
- Hemidystonia associated with Alexander disease.
- A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia.
- Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD Probe study.
- Presentation, diagnostic hurdles, and therapeutic measures in a case of isolated coccidioidomycosis meningitis in an immunocompetent individual.
- Assessment of capacity to consent in a Huntington disease clinical trial: Implications for future clinical trial design in neurodegenerative disease populations.
- A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia.
- Clinical relevance of treatment with onabotulinumtoxina in patients with cervical dystonia: Results from the CD Probe study.
- Potential new uses of botulinum toxin injections in movement disorders.
- Predictors of onabotulinumtoxinA response in patients with cervical dystonia.
- Understanding, predicting, and preventing falls in progressive supranuclear palsy.
- Objectives of the MDS rare movement disorders study group.
- A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.
- Predictors of onabotulinumtoxinA treatment response in patients with cervical dystonia.
- Apraclonidine in blepharospasm.
- Apraclonidine in the treatment of ptosis.
- A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.
- Paradoxical worsening dystonia after deep brain stimulation in a patient with neurodegeneration with brain iron accumulation.
- XCiDaBLE: Observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the USA.
- Progressive supranuclear palsy and statin use.
- DBS experience at a tertiary care referral center.
- American multiple system atrophy natural history study.
- Cervical dystonia and work productivity: Results from the cervical dystonia patient registry for the observation of onabotulinumtoxinA efficacy.
- Dystonia-spasticity in a patient with a novel SLC25A12 mutation.
- Clinical utility of apraclonidine in ptosis.
- Reliability of the severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2).
[Oral Presentation]
- XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Final results from the blepharospasm cohort.
- The impact of cervical dystonia on work productivity: An analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
- Dystonia-spasticity in a patient with a novel SLC25A12 mutation.
- SUNCT responding to botulinum toxin.
- Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE).
- Long-term effects of botulinum toxin injections.
- Treatment patterns and patient disposition in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
- Convergent validity of the revised motor and psychiatric TWSTRS modules of the Comprehensive Cervical Dystonia Rating Scale (CCDRS).
- Effectiveness and safety in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
- MER vs. MRI guidance in placement of DBS electrodes for Parkinson's disease.
- Methodology for a symptomatic impact study using a portable essential tremor (ET) monitor to direct therapeutic interventions.
- Reliability and validity of the revised TWSTRS psychiatric module (TWSTRS-PSYCH) of the Comprehensive Cervical Dystonia Rating Scale (CCDRS).
- Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Treatment patterns and subject disposition.
- Clinimetric testing of the modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS).
[Platform Presentation]
- Treatment outcomes in Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE).
- Alleviating maneuvers (sensory tricks) in cervical dystonia.
- Dopamine transporter imaging in essential tremor with and without parkinsonian features.
[Platform Presentation]
- Hereditary spastic paraplegia due to a novel mutation in SPG11 gene presenting as dopa responsive dystonia, parkinsonism and spasticity.
- Efficacy and safety of IPX066, a carbidopa-levodopa, extended-release formulation, in early Parkinson's disease.
- The long-term safety and efficacy of thalamic deep brain stimulation in essential tremor.
- Minimal clinically important changes in UPDRS scores in early PD in rotigotine clinical trials.
- Continuous home monitoring of essential tremor using motion sensors.
- Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Baseline demographic and clinical characteristics.
- Sensory tricks (corrective maneuvers) in cervical dystonia.
- Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa (SETTLE).
- Long-term safety of neurotrophic factor gene therapy using AAV2-neurturin (CERE-120) in Parkinson's disease.
- Movement disorders in golfers.
- XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Interim results from the first 145 subjects with cervical dystonia.
- Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE): Baseline demographic and clinical characteristics.
- Continuous home monitoring of essential tremor using motion sensors.
- Long-term efficacy, safety, and side effect profile of botulinum toxin injections in dystonia - a 20-year follow-up.
- Safinamide add on to L-dopa: A randomized, placebo-controlled, 24-week global trial in patients with Parkinson's disease (PD) and motor fluctuations (SETTLE).
- Zolpidem improves tardive dyskinesia with and without akathisia.
- Clinical and imaging data in essential tremor with parkinsonian features.
- The long-term efficacy and safety of fluphenazine in patients with Tourette syndrome.
- Frontostriatal changes detected by DTI tractography in Parkinson's disease dementia.
- Movement disorders in golfers - Four case reports and a brief review of literature.
- GABAB receptor limbic encephalitis: Case report and a brief literature review.
- Clinical assessment of the effect of tetrabenazine on motor function in moderate Huntington disease.
- A prospective, observational trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia
(CD) or blepharospasm in the United States - Preliminary baseline results on the health impact of
CD on patients using the cervical dystonia impact profile (CDIP).
- A prospective, observational trial evaluating Xeomin [IncobotulinumtoxinA] for cervical dystonia or blepharospasm in the US - Preliminary baseline results for patients with blepharospasm.
- Mutations in the novel protein PRRT2 cause infantile convulsions with paroxysmal kinesigenic dyskinesia.
- Flu-like and systemic symptoms following treatment with botulinum toxins.
- AAV2-Neurturin (CERE-120) and Parkinson's disease: The safety and feasibility of combined substantia nigral and putaminal stereotactic targeting via a phase 1/2b clinical trial in advanced Parkinson's disease.
- Cervical dystonia subtypes baseline results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE).
- Clinical assessment of the effect of tetrabenazine on motor function in moderate Huntington's disease.
- XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia (CD) or blepharospasm in the United States - Preliminary baseline results on the health impact of CD on patients using the cervical dystonia impact profile.
- XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm in the United States - Preliminary baseline results for patients with blepharospasm.
- Analysis of CYP2D6 genotype and response to tetrabenazine.
- Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome.
- Neuroprotection by neuropeptide orexin A in a cellular model of Parkinson's disease.
- Entropy measurements in pallidal neurons in dystonia and Parkinson disease.
- Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease.
- Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease.
- Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease.
- Anti-parkinsonian effects of Nurr1 activator in UPS impairment induced animal model of Parkinson's disease.
- Flu-like and systemic symptoms following treatment with botulinum toxins.
- Severity of cervical dystonia: Baseline characteristics from the Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CDPROBE).
- Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease (HD).
- IncobotulinumtoxinA (Xeomin®) is well tolerated for the treatment of blepharospasm when injected according to patient needs.
- Analysis of the behavioral features conferred by the intermediate allele for Huntington disease in the prospective Huntington at risk observational study (PHAROS).
- XCiDaBLE: A phase 4, observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Preliminary baseline disease severity and quality of life data.
- Dystonic respiratory dysregulation and other breathing disorders associated with dystonia.
- Genome-wide association study of Gilles de la Tourette Syndrome.
- Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease.
- Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease (HD).
- Diagnostic reliability of DaTscan in movement disorders.
- Horizontal and vertical eye movements in Huntington's disease patients and age matched controls.
- Association of PSP with chemical occupational exposure factors.
- Sustained efficacy of long-term incobotulinumtoxin-a (Xeomin®; botulinum neurotoxin type-a, free from accessory proteins) treatment for cervical dystonia, blepharospasm and upper limb post-stroke spasticity.
- Deep brain stimulation: Hardware related complications in patients with movement disorders.
- The long-term impact of early versus delayed treatment with rotigotine transdermal system in patients with early-stage, idiopathic Parkinson's disease.
- IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with blepharospasm across dosing intervals in a repeated dose-study.
- The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism.
- Correlation of patient impression with the cervical dystonia impact questionnaire.
- Convergence spasm in conversion disorders: Prevalence in psychogenic and other movement disorders compared to controls.
- Constant current DBS: A randomized controlled clinical trial in Parkinson's disease: 12 month results.
- Essential tremor quantification during activities of daily living.
- Identification of a novel downstream target of Nurr1 transcription factor for midbrain dopamine neuron development.
- Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE): Study design of a prospective observational registry.
- A mechanistic study of proteasome inhibition-induced iron misregulation in dopaminergic neuron degeneration.
- Amplitude fluctuations in essential tremor. A prospective study.
- A randomized controlled trial of constant current DBS active stimulation versus off stimulation in Parkinson's disease.
- Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naive early Parkinson's disease (APEX-PD trial).
- Patients' perspective of tetrabenazine two years after FDA approval.
- Alpha-synuclein: Possible link between Parkinson's disease and melanoma.
- Brain glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG33 repeat length in the Huntington's disease gene.
- Postural instability and gait difficulty scores from the MDS-UPDRS.
- Assessing dissociative pathology in psychogenic movement disorders: Clinical utility of the Dissociative Experiences Scale-II.
- Safety data in a randomized controlled trial of constant current deep brain stimulation versus lead placement alone for treatment of motor fluctuations in Parkinson's disease.
- Peripheral trauma and movement disorders: A systematic review of reported cases.
- Deep brain stimulation system revision, and hardware related complications in 512 patients with movement disorders.
- Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of pain-related outcomes.
- Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously treated with botulinum toxin.
- Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously naive to botulinum toxin treatment.
- Intermediate CAG repeats: Analysis of the cooperative Huntington's observational research trial.
- Essential tremor quantification during activities of daily living.
- Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of physician-reported outcomes.
- Double-blind, placebo-controlled fixed-dose trial of IPX066, a novel carbidopa-levodopa (CD-LD) extended-release formulation, in early Parkinson's disease (APEX-PD).
- AMPK-mediated neuroprotection on cellular models of Parkinson's disease.
- Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of patient-reported outcomes.
- Postural instability and gait difficulty scores from the MDS-UPDRS.
- Psychosocial profiles of psychogenic movement disorder patients with non-epileptic seizures and other abnormal motor manifestations.
- Diffusion tensor tractography of the internal capsule in depressed and anxious Parkinson's disease patients.
- Longitudinal analysis of intermediate CAGn repeat length expansion in the prospective Huntington's disease at-risk observational study (PHAROS).
- CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — preliminary safety data.
- Validation of a cervical dystonia questionnaire (CDQ).
- Prospective 5-year natural history study of probable multiple system atrophy (MSA) in 175 North American subjects.
- Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with blepharospasm.
- Validation of a motor screen for undiagnosed parkinsonism: The Baylor Functional Assessment Screen (BFAS).
- CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — CD impact on quality of life (QOL) and patient reported outcomes (PRO).
- Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
- Use of an interactive voice response system by patients with blepharospasm receiving repeated injections of NT 201 (botulinum neurotoxin type A free from complexing proteins).
- Assessing patients' access to tetrabenazine (Xenazine) after FDA approval.
- Curcumin accelerates the clearance of mutant alpha-synuclein and injured mitochondria via autophagy induction.
- SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases.
- Neuropsychological assessment of monolingual Spanish speaking Parkinson's disease patients in the United States pre and post STN-DBS.
- Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to 7 years.
- Retrospective study of the therapeutic effect of deep brain stimulation in multiple system atrophy.
- Orthostatic tremor: A review of 40 cases.
- Upper face chorea in Huntington disease.
- Effect of tetrabenazine (TBZ) on motor function in patients with Huntington disease (HD).
- CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of onabotulinumtoxin A injections in cervical dystonia (CD) patients — Interim patient reported outcome data.
- CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of repeated onabotulinumtoxin A injections in cervical dystonia (CD) patients — Preliminary baseline data.
- Clinical correlates of eye movements in Huntington disease.
- Ubiquitin proteasome system impairment mouse model of Parkinson's disease.
- HIF-1α-mediated neuroprotection on MPP+-induced apoptosis in SH-SY5Y cells.
- The natural progression of clinical symptoms in Parkinson's disease may not be faster in the earlier stages: Results from the ADAGIO delayed-start study.
- Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to seven years.
- Asian over representation among patients with hemifacial spasm compared to cranial dystonia.
- A novel set shifting fMRI task identifies differences in brain activation in Parkinson's disease and healthy controls.
- Rasagiline provides symptomatic benefit in early Parkinson's disease (PD).
- Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD).
- Treatment of dysautonomia associated with Parkinson's disease.
- Influence of levodopa and psychotropic medication on emotional and physical symptoms of depression before and following STN-DBS for the treatment of Parkinson's disease.
- Alternating fluency performance following bilateral STN DBS for the treatment of Parkinson's disease.
- AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD): Efficacy and safety results from a controlled Phase 2 clinical trial.
- Long-term deep brain stimulation for essential tremor: 12- year clinicopathologic follow up and literature review.
- Double-blind, randomized, placebo-controlled, cross-over trial of pregabalin in essential tremor.
- Impact of STN-DBS on health-related quality of life in patients with Parkinson's disease.
- Tourette syndrome in adults.
- Efficacy and safety of NT 201 (botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients.
- Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients.
- A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome.
- Transcription factor PITX3 in Parkinson's disease.
- Correlation between Kinesia system assessments and clinical TETRAS scores in patients with essential tremor.
- 17-AAG protects against rotenone-induced apoptosis in SHSY5Y cells via HSP70 induction.
- Resveratrol, a polyphenol found in red wine, protects against rotenone-induced apoptosis through autophagy induction.
- The course of depressive symptoms in early Parkinson's disease.
- Mood differences between women diagnosed with psychogenic movement disorders and psychogenic seizures.
- The written and oral administration of the Symbol Digit Modality Test in Huntington disease.
- Efficacy and safety of NT 201 (neurotoxin free from complexing proteins) in cervical dystonia.
- Efficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in blepharospasm.
- Rapamycin protects against rotenone-induced apoptosis through autophagy induction in SH-SY5Y cells.
- A controlled study of the long-term cognitive outcome of bilateral subthalamic nucleus deep brain stimulation.
- Progressive DA neuron degeneration induced by targeting administration of proteasome inhibitor in SN.
- Unusual motor-phonic tic mimicking essential palatal myoclonus (EPM).
- Correlation between clinical rating of parkinsonian and essential tremor and quantitative assessments.
- The essential tremor rating assessment scale (TETRAS).
- Spinocerebellar Ataxia 8: Variable phenotype and unique pathogenesis.
- Evaluation of a Parkinson's disease screening questionnaire for use in a community-based setting.
- The role of dopaminergic medication doses in impulse control disorders (ICD) in Parkinson's disease (PD).
- Expanded study of NURR1 gene expression in patients with Parkinson's disease.
- Deep brain stimulation of the subthalamic nucleus for peripherally-induced parkinsonism.
- A randomized, double-blind, placebo-controlled study of atomoxetine for freezing of gait in Parkinson's disease.
- Rapamycin rescues lactacystin-induced dopaminergic neuron injury in vivo.
- Neuropsychological functioning of Parkinson's disease patients two years post subthalamic nucleus deep brain stimulation surgery.
- Experience with MRI safety and DBS: Data from the National Parkinson Foundation Centers of Excellence.
- Volume and nature of patient telephone calls in a large movement disorders center.
- Characteristics of Archimedean spiral drawing in patients with psychogenic tremor.
- Morbidity associated with psychogenic movement disorders in children.
- Phenomenology of psychogenic movement disorders in children.
- New version of the UPDRS (MDS-UPDRS): Factor analysis.
- Craving for sweets and other compulsive behaviors in patients with Parkinson's disease.
- Acamprosate improves impulse control disorders in Parkinson's disease.
- Treatment of freezing of gait in Parkinson's disease with deep brain stimulation of the pedunculopontine nucleus.
- Role of deferoxamine and autophagy induction in rotenone-induced apoptosis.
- Changes in emotional versus physical symptoms of depression following sub-thalamic nucleus deep brain stimulation for Parkinson's disease.
- Hemidystonia-hemiatrophy syndrome.
- Rotigotine transdermal patch as a treatment of nocturnal symptoms in patients with idiopathic Parkinson's disease.
- Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version.
- Clinical features of movement disorders in hemochromatosis.
- Deep brain stimulation for tardive dyskinesia and akathisia.
- Health related quality of life in essential tremor patients undergoing deep brain stimulation.
- Health related quality of life in Parkinson's disease patients undergoing deep brain stimulation.
- Switch from an oral dopamine agonist to rotigotine transdermal patch in Parkinson's disease.
- Motor and behavioral outcomes after bilateral GPi deep brain stimulation for severe Tourette syndrome.
- Shoulder pain in Parkinson's disease.
- The other Babinski sign in hemifacial spasm.
- The specificity and sensitivity of "applause sign" in differentiating PSP and other parkinsonian syndromes.
- Brain permeable iron chelators M-30 and AK-28 rescue degenerated nigral dopamine neurons in animal model of PD.
- Malignant Tourette syndrome.
- Three parkin mutations in a family with Parkinson's disease.
- Autopsy-proven Huntington disease with 29 trinucleotide repeats.
[Previously Presented]
- Autophagy induction and its neuroprotection on neurotoxin-induced cell injury relevant to Parkinson's disease.
- Motor overflow, contralateral dystonia and mirror movements in focal hand dystonia.
- Head injury with amnesia and risk of multiple system atrophy (MSA).
- Novel brain permeable iron chelators prevent lactacystin induced ubiquitin-proteasome inhibition and degeneration of nigrostriatal dopamine neurons.
- Proteasome inhibition in substantial nigra induces sustained dopamine cells degeneration.
- Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor.
- The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor.
- Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life.
- Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population.
- Hyperhidrosis due to thalamic deep brain stimulation in a patient with essential tremor.
- Clinical features that distinguish psychogenic and essential tremor.
- Short-term effects of tetrabenazine on chorea associated with Huntington disease.
[Previously Presented]
- Autopsy-proven Huntington disease with 29 trinucleotide repeats.
- Enhancement of autophagy and neuroprotection by rapamycin in lactacystin-induced injury of dopaminergic neurons.
- Executive dysfunction and comorbid conditions in Tourette syndrome.
- Craving sweets in Parkinson's disease.
- GPI deep brain stimulation for Tourette syndrome improves tics and psychiatric co-morbidities.
- Overflow, contralateral and mirror hand dystonia.
- Hemiparkinsonism-hemiatrophy syndrome.
- Different faces of hemifacial spasm: Etiological classification.
- Runner's dystonia.
- Relationship of MRI localization and cognition in DBS.
- Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor.
- A Mexican pedigree with Parkinson's disease, essential tremor and bell's palsy associated with parkin but not HS1BP3 gene mutation.
- Genetic analysis of the SLITRK1 gene in Caucasian patients with Tourette syndrome.
- Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life.
[Previously Presented]
- Medications associated with the onset of tardive dyskinesia.
- Short-term effects of tetrabenazine on chorea associated with Huntington disease.
- Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders.
- Long term safety of deep brain stimulation for the treatment of Parkinson's disease.
- Nurrl deficiency predisposes to apoptosis induced by lactacystin in SH-SY5Y cells in vitro.
- Bilateral GPI deep brain stimulation for Tourette syndrome.
- Frontostriatal cognitive functioning 6 months following bilateral subthalamic nucleus deep brain stimulation.
- Botulinum toxin type B Observational Study (BOS).
- Genetic analysis of G309D and W4370PA mutations of PINK1 in Parkinson's disease.
- New version of the UPDRS: Development methods and working document for field testing.
- A variant in the HS1-BP3 gene is associated with familial essential tremor.
- Convergence spasm and other psychogenic eye movement disorders.
- Tics associated with other disorders.
- HSP70 inducer VPA inhibits rotenone-induced apoptosis in SH-SY5Y cells.
- Characteristics of Parkinson's disease in patients with childhood-onset essential tremor.
[Previously Presented]
- Botulinum toxin treatment for oromandibular dystonia and bruxism in patients with Tourette syndrome.
- Gait and balance assessment in parkinsonian disorders.
- Small interfering RNA (SiRNA) targeting the PINK1 induces apoptosis in human SH-SY5Y cells.
- Reduced NURR1 gene expression affects expression of dopaminergic phenotypic markers and Parkinson's disease-related genes.
- Globus pallidus deep brain stimulation in dystonia.
- Relationship among psychiatric, motor and cognitive functioning in non-demented individuals with Parkinson's disease.
- Tetrabenazine: Does prior history of depression preclude this drug as a treatment option?
- Botulinum toxin type B Observational Study (BOS).
- Prevalence of cervical dystonia and spasmodic torticollis in the United States.
- Medications associated with the onset of tardive dyskinesia.
- Predictors of battery life for the Activa® Soletra 7426 neurostimulator.
- Subthalamic deep brain stimulation in patients with a previous pallidotomy.
- Characteristics of Parkinson's disease in patients with childhood-onset essential tremor.
- Parkinsonism associated with adalimumab in a patient with rheumatoid arthritis.
- Botulinum toxin serotype A compared to B in cervical dystonia: Randomized, double-blind, parallel study.
- The safety of deep brain stimulation in patients with Parkinson's disease, essential tremor, and other movement disorders.
- Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas.
- The Tremor Rating Scale (TRS).
- Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome.
- Tetrabenazine: Effective treatment for tardive dyskinesia.
- A multicenter, double-blind, placebo-controlled trial of topiramate in essential tremor.
- Nurr1 gene targeting therapy for Parkinson disease.
- The pharmacological and biological effects of pramipexole on dopamine neuron associated genes: DAT, VMAT-2, and Nurr1.
- Young-onset versus late-onset Parkinson's disease: Clinical features and disease progression.
- Long-term prognosis of psychogenic movement disorders.
- Psychogenic dystonia: Clinical characteristics and long-term progression.
- A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox) and botulinum toxin, type B (Myobloc) on systemic and ocular autonomic symptoms and physiology in patients with cervical dystonia.
- Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders.
- Is depression a predictor of outcome after bilateral subthalamic deep brain stimulation in patients with Parkinson's disease?
- Camptocormia: Pathogenesis, classification and response to therapy.
- Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia.
- Haplotype analysis at the ETM2 locus in American and Singaporean populations with familial essential tremor.
- Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
- Essential tremor in children.
- Psychogenic tremor: Long-term outcome.
- Effects of ropinirole on progression of parkinsonism in Nurr1-deficient mice and its underlying mechanisms.
- Dopaminergic properties and anti-parkinsonian effects of IPX750 in rodent models of Parkinson's disease.
- The pharmacological and biological effects of pramipexole on dopamine transporter.
- Decreased Nurr1 mRNA in peripheral blood lymphocytes in Parkinson's disease.
- The efficacy and safety of fluphenazine in patients with Tourette syndrome.
- A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox®) and botulinum toxin, type B (Myobloc™) on autonomic symptoms and physiology in patients with cervical dystonia.
- Haplotype analysis of unrelated individuals with familial essential tremor.
- Comparison of postoperative improvement of staged bilateral subthalamic stimulation in patients with advanced Parkinson's disease.
- Apolipoprotein E controls risk and age at onset of Parkinson disease.
- Glutathione S-Transferase, Omega-1 (GSTO1) modifies age at onset of Alzheimer disease and Parkinson disease.
- The epidemiology of myoclonus in the medical and surgical intensive care unit (ICU).
- Specific mitochondrial haplogroups affect risk for late-onset Parkinson disease.
- Treatment of hypophonia with collagen vocal fold augmentation in patients with parkinsonism.
- Age-related tolerability of tetrabenazine.
- Tetrabenazine in the treatment of Tourette syndrome.
- Premonitory sensations in tics.
- Reduced Nurr1 expression increases the susceptibility to dopaminergic toxins via nitric oxide.
- Computerized posturography balance assessment of patients with bilateral vim deep brain stimulation.
- Upregulation of Nurr1 gene expression by dopamine receptor agonist pramipexole in human neuroblastoma SHSY-5Y cells.
- Reliability of limits of stability measures in Parkinson's disease.
- Minocycline in Huntington's disease: A pilot study.
- Gait and Balance Scale (GABS): Validation and utilization.
- Experience with bilateral subthalamic nucleus (STN) stimulation for Parkinson's disease (PD).
- Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson's disease.
- Pleuropulmonary fibrosis after 11 years of pergolide treatment.
- The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia: Results of the first US study.
- Dystonia in Friedreich's ataxia.
- The prevalence of restless legs syndrome in patients with Parkinson's disease.
- Exploring the relationship between Parkinson's disease and restless legs syndrome.
- Olanzapine treatment for dopaminergic induced hallucinations.
- Daytime sleepiness in patients with Parkinson's disease.
- Unilateral thalamic deep brain stimulation for essential tremor and Parkinson's disease: Effects of stimulation on the non-target limb and rebound augmentation.
- Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.
- Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.
- The impact of extended deprenyl treatment in Parkinson's disease patients not requiring levodopa therapy.
- The alien hand and related signs.
Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 12-16, 2020)
American Academy of Neurology (AAN)
72nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)
American Academy of Neurology (AAN)
71st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)
Huntington Study Group (HSG)
Annual Meeting in Houston, Texas (Nov. 8-10, 2018)
Movement Disorder Society (MDS)
22nd International Congress of Parkinson's Disease and Movement Disorders in Hong Kong, China (Oct. 5-9, 2018)
American Academy of Neurology (AAN)
70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)
Movement Disorder Society (MDS)
21st International Congress of Parkinson's Disease and Movement Disorders in Vancouver, BC, Canada (June 4-8, 2017)
American Academy of Neurology (AAN)
69th Annual Meeting in Boston, Mass. (April 22-28, 2017)
International Neurotoxin Association (INA)
Toxins 2017 3rd International Conference in Madrid, Spain (Jan. 18-21, 2017)
Movement Disorder Society (MDS)
20th International Congress of Parkinson's Disease and Movement Disorders in Berlin, Germany (June 19-23, 2016)
American Academy of Neurology (AAN)
68th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)
Movement Disorder Society (MDS)
19th International Congress of Parkinson's Disease and Movement Disorders in San Diego, Calif. (June 14-18, 2015)
American Academy of Neurology (AAN)
67th Annual Meeting in Washington, DC (April 18-25, 2015)
International Neurotoxin Association (INA)
Toxins 2017 2nd International Conference in Lisbon, Portugal (Jan. 14-17, 2015)
Movement Disorder Society (MDS)
18th International Congress of Parkinson's Disease and Movement Disorders in Stockholm, Sweden (June 8-12, 2014)
American Academy of Neurology (AAN)
66th Annual Meeting in Philadelphia, Penn. (April 26 - May 3, 2014)
American Neurological Association (ANA)
138th Annual Meeting in New Orleans, La. (Oct. 13-15, 2013)
Movement Disorder Society (MDS)
17th International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia (June 16-20, 2013)
American Academy of Neurology (AAN)
65th Annual Meeting in San Diego, Calif. (March 16-23, 2013)
International Neuropsychological Society (INS)
41st Annual Meeting in Montreal, Waikoloa, Hawaii (Feb. 6-9, 2013)
Baylor College of Medicine (BCM)
Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012)
American Neurological Association (ANA)
137th Annual Meeting in Boston, Mass. (Oct. 7-9, 2012)
Movement Disorder Society (MDS)
16th International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland (June 17-21, 2012)
American Academy of Neurology (AAN)
64th Annual Meeting in New Orleans, La. (April 21-28, 2012)
Society for Neuroscience (SFN)
41st Annual Meeting in Washington, DC (Nov. 12-16, 2011)
American Neurological Association (ANA)
136th Annual Meeting in San Diego, Calif. (Sept. 25-27, 2011)
European Federation of Neurological Societies (EFNS)
15th Congress in Budapest, Hungary (Sept. 10-13, 2011)
Movement Disorder Society (MDS)
15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada (June 5-9, 2011)
American Academy of Neurology (AAN)
63rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)
AD/PD
10th International Congress on Alzheimer's and Parkinson's Diseases in Barcelona, Spain (March 9-13, 2011)
Movement Disorder Society (MDS)
14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010)
American Academy of Neurology (AAN)
62nd Annual Meeting in Toronto, Canada (April 10-17, 2010)
World Federation of Neurology (WFN)
XVIII World Congress on Parkinson's Disease and Related Disorders in Miami Beach, Fla. (Dec. 13-16, 2009)
Baylor College of Medicine (BCM)
Current Neurology 2009 in Houston, Texas (Oct. 31 - Nov. 1, 2009)
Society for Neuroscience (SFN)
39th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2009)
Movement Disorder Society (MDS)
13th International Congress of Parkinson's Disease and Movement Disorders in Paris, France (June 7-11, 2009)
American Academy of Neurology (AAN)
61st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)
6th International Congress on Mental Dysfunctions and Other Non-Motor Features in Parkinson's Disease and Related Disorders
Dresden, Germany (Oct. 16-19, 2008)
American Neurological Association (ANA)
133rd Annual Meeting in Salt Lake City, Utah (Sept. 21-24, 2008)
Movement Disorder Society (MDS)
12th International Congress of Parkinson's Disease and Movement Disorders in Chicago, Ill. (June 22-26, 2008)
American Academy of Neurology (AAN)
60th Annual Meeting in Chicago, Ill. (April 12-19, 2008)
Movement Disorder Society (MDS)
11th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey (June 3-7, 2007)
American Academy of Neurology (AAN)
59th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)
8th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)
Movement Disorder Society (MDS)
10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan (Oct. 30 - Nov. 2, 2006)
American Neurological Association (ANA)
131st Annual Meeting in Chicago, Ill. (Oct. 8-11, 2006)
American Academy of Neurology (AAN)
58th Annual Meeting in San Diego, Calif. (April 1-8, 2006)
International Neuropsychological Society (INS)
34th Annual Meeting in Boston, Mass. (Feb. 1-4, 2006)
American Neurological Association (ANA)
130th Annual Meeting in San Diego, Calif. (Sept. 25-28, 2005)
American Academy of Neurology (AAN)
57th Annual Meeting in Miami Beach, Fla. (April 9-16, 2005)
Movement Disorder Society (MDS)
9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, La. (March 5-8, 2005)
American Neurological Association (ANA)
129th Annual Meeting in Toronto, Canada (Oct. 4-5, 2004)
Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders
18th Annual Symposium in Toronto, Canada (Oct. 3, 2004)
Movement Disorder Society (MDS)
8th International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy (June 13-17, 2004)
American Academy of Neurology (AAN)
56th Annual Meeting in San Francisco, Calif. (April 24 - May 1, 2004)
American Society for Experimental NeuroTherapeutics (ASENT)
6th Annual Meeting in Bethesda, Md. (March 11-13, 2004)
International Neuropsychological Society (INS)
32nd Annual Meeting in Baltimore, Md. (Feb. 4-7, 2004)
American Academy of Neurology (AAN)
55th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)
Movement Disorder Society (MDS)
7th International Congress of Parkinson's Disease and Movement Disorders in Miami, Fla. (Nov. 10-14, 2002)
American Neurological Association (ANA)
127th Annual Meeting in New York City, N.Y. (Oct. 12-16, 2002)
Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins
International Conference in Hannover, Germany (June 8, 2002)
American Academy of Neurology (AAN)
53rd Annual Meeting in Philadelphia, Penn. (May 5-11, 2001)
Movement Disorder Society (MDS)
6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000)
American Academy of Neurology (AAN)
52nd Annual Meeting in San Diego, Calif. (April 29 - May 6, 2000)
American Academy of Neurology (AAN)
46th Annual Meeting in Washington, DC (May 1-7, 1994)
International Neuropsychological Society (INS)
22nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)
American Neurological Association (ANA)
118th Annual Meeting in Boston, Mass. (Oct. 18-20, 1993)
American Academy of Neurology (AAN)
43rd Annual Meeting in Boston, Mass. (April 21-27, 1991)